<DOC>
	<DOCNO>NCT01023347</DOCNO>
	<brief_summary>This randomize clinical trial Paclitaxel ( Genexol® ) Cisplatin versus Paclitaxel load polymeric micelle ( Genexol-PM® ) Cisplatin advance non small cell lung cancer .</brief_summary>
	<brief_title>A Trial Paclitaxel ( Genexol® ) Cisplatin Versus Paclitaxel Loaded Polymeric Micelle ( Genexol-PM® ) Cisplatin Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histological cytological evidence locally advance , metastatic recurrent NSCLC ( stage IIIB Iv ) At least one measurable lesion ( ) RECIST criteria No previous palliative chemotherapy Age 18 high . ECOG PS 02 Life expectancy least 3 month . Adequate hematologic , hepatic , renal function Adequate bone marrow function ( ≥ ANC 1,500/ul , ≥ platelet 100,000/ul ) Adequate liver function ( ≤ Total bilirubin ≤ 1.5 upper normal limit , ≤ AST/ALT x 2.5 upper normal limit , Alkaline phosphatase ≤ 2.5 upper normal limit ) Adequate renal function ( ≤ serum creatinine 1.5 mg/dl ) Written inform consent No prior chemotherapy NSCLC Patients malignancy ( NSCLC ) , except adequately treat nonmelanoma skin cancer situ carcinoma cervix . Peripheral neuropathy ≥ grade 2 ( NCI CTC , version 3.0 ) Clinically significant cardiac disease ( medically uncontrollable heart disease ) Active infection serious medical illness Contraindication drug contain chemotherapy regimen Pregnant lactate woman exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>NSCLC</keyword>
</DOC>